AI주식인사이트AI Stock Insight
B

SK바이오팜

326030KOSPI

56.5 / 100

Reference Date: 2026-10-23

Financial Score28.0 / 40
News Sentiment12.5 / 25
Momentum6.0 / 20
Disclosure10.0 / 15
AI Analysis: the debt ratio is very low with excellent financial health but PBR raises overvaluation concerns. Declined 6.3% over the past month, with no recent news.

Company InformationBased on 2025 Annual Report

Business Overview

SK Bios制药 was established in 1993, focusing on innovative drug development for epilepsy and successfully expanding its technology exports to multiple countries, including the U.S. and Europe. Its flagship products, Xenobamate and Solriamfetol, are sold in global markets, with sales reaching 70.67 billion KRW in 2025. The company is also advancing into new therapeutic modalities such as RPT and TPD to expand into oncology.

Number of Employees

272people

Average Salary

109.0M KRW

Score Calculation Basis

Detailed Financial Score

PER
21.71Industry Average 15.003.0Point

Higher than industry avg (caution)

PBR
7.01Industry Average 1.200.0Point

5.8x industry avg (risky)

ROE
36.17Industry Average 8.007.0Point

4.5x industry avg (excellent)

Debt Ratio
9.30Industry Average 100.008.0Point

Half of industry avg (excellent)

Trend 2023~202510.0 / 10 points
Revenue Growth Rate
3.0 / 3

Avg ▲41.7% (2-year basis)

Operating Profit Growth Rate
3.0 / 3

Avg ▲234.2% (2-year basis)

ROE Trend
4.0 / 4

Avg ROE 25.3% (improving, 3yr)

Detailed News Sentiment

0 totalPositive 0Neutral 0Negative 0

Detailed Momentum

52-week position1.0Point

Near 52w low (7%, downtrend)

Current 74,000Won52-week high 140,70052-week low 68,800
1-month return2.0Point

1m -6.33% (slight drop)

Volume trend3.0Point

Volume flat

Detailed Disclosure

0 totalPositive 0Neutral 0Negative 0